Search global stocks & ETFs...Ctrl K
Learn Mode
CRISPR Therapeutics AGCRSP
$60.08
$4.46 (8.019%)
$59.89
-$0.19 (-0.315%)
CRSP
Stock Profile
08-03
Recommended Metric
Score Card
Explore Scores Tab
2.24
Bad
Valuation Score
Key Score
2.00
Bad
Management
5.00
Very Good
Growth
5.00
Very Good
Profitability
1.00
Very Bad
Fin. Health
1.00
Very Bad
Dividends
--
--
Analyst
5.00
Very Good
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$60.08
Baseline
High
$305.55
▲
408.57%
Avg
$81.92
▲
36.34%
Low
$33.33
▼
-44.52%
Analyst Ratings based on 32 Analysts
Strong Buy
722%
Buy
1238%
Hold
1238%
Sell
103%
Strong Sell
000%
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.Read More
Stock News
View All Updates
News100%Bullish
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday
1dBenzinga
10 Health Care Stocks With Whale Alerts In Today’s Session
2dBenzinga
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
3dSeekingAlpha
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade)
1wSeekingAlpha
3 Companies Redefining Healthcare Innovation
1wSeekingAlpha
Investors Flee Cathie Wood's ARKK ETF As It Trails S&P 500, Nasdaq 100 By Far
1wBenzinga
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
3wSeekingAlpha
CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript
4wSeekingAlpha
CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript
4wSeekingAlpha
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
4wYahoo
Is CRISPR Therapeutics (CRSP) One Of The Under-The-Radar Stocks With Massive Upside For 2026?
5wYahoo
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
5wYahoo
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
5wYahoo
Assessing CRISPR Therapeutics (CRSP) Valuation After Narrower Q1 2026 Loss And Pipeline Progress
5wYahoo
CRISPR Therapeutics AG (CRSP) Reports Q1 2026 Results
5wYahoo
These Are The Upcoming Catalysts For Crispr Therapeutics Stock
6wSeekingAlpha
[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
6wYahoo
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
6wYahoo
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
6wYahoo
CRISPR Therapeutics Enters Second Phase As CASGEVY Uptake And Data Build
6wYahoo
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
6wYahoo
Bernstein Maintains Market Perform on CRISPR Therapeutics, Raises Price Target to $56
7wBenzinga
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2026 Update
7wSeekingAlpha
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
7wSeekingAlpha
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
7wYahoo
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
7wYahoo
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
8wYahoo
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $82
8wBenzinga
Is It Time To Reconsider CRISPR Therapeutics (CRSP) After A 58% One Year Rally?
8wYahoo
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
8wYahoo
Crispr Therapeutics Q1 Earnings: Casgevy Growth, H2 In-Vivo Catalysts Make Buy Case
8wSeekingAlpha
Stock Picks From Seeking Alpha's April 2026 New Analysts
8wSeekingAlpha
VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth
8wYahoo
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
8wYahoo
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
8wYahoo
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
8wYahoo
Legend Biotech: Undervalued Leader In The CAR-T Race
10wSeekingAlpha
CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
11wSeekingAlpha
Transcript : CRISPR Therapeutics AG Presents at 25th Annual Needham Virtual Healthcare Conference, Apr-13-2026 02
11wFinnhub
Undercovered Dozen: CVR Energy, Greystone Housing, Conagra Brands, And More
12wSeekingAlpha
A Turning Point For Crispr Therapeutics As Commercial Growth Accelerates
13wSeekingAlpha
I Expect Crispr Therapeutics To Break Out As 2026 Revenue Exceeds Expectations
13wSeekingAlpha
Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Raises Price Target to $110
15wBenzinga
CRISPR Therapeutics Prices Upsized $550M Convertible Senior Notes Offering Due 2031 With Option For Additional $50M, Expected To Close March 16, 2026
16wBenzinga
What's Going On With CRISPR Therapeutics Stock Today?
16wBenzinga
CRISPR Therapeutics shares are trading lower after the company announced a $350 million convertible senior notes offering.
16wBenzinga
Reported Earlier: CRISPR Therapeutics Plans $350M Convertible Note Offering, Maturing 2031, To Fund Corporate Purposes
16wBenzinga
FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
16wBenzinga
Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take
16wSeekingAlpha
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
16wBenzinga
